Loading company
Precipio, Inc.
PRPO · Nasdaq · ·
$23.49-2.8%Sep 29 close
- 1M
- -15.4%
- 6M
- -5.0%
- 1Y
- +14.6%
- 5Y
- -60.6%
PRPO · Nasdaq · ·
$23.49-2.8%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $7M | $5.7M | +24.18% |
| Profit | -$219K | $74K | -395.95% |
| Profit per share | -$0.12 | $0.05 | -340.00% |
| Free Cash Flow | $528K | $294K | +79.59% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Precipio, Inc. has no earnings call transcript available.
“As anticipated, Q2 operating performance reflects a healthy recovery and continued momentum across the business, with customer growth generating quarterly revenue surpassing $7M for the first time in Company history. Product revenues increased 21% from the previous high of $750K in Q4-2025, and cash increased to over $3M.”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis. Availability of Other Information
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Precipio, Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.